Voyager CEO Al Sandrock outlines a focused strategy: remain specialists in neurology, but broaden the therapeutic modalities (gene therapy, proteins, oligonucleotides). This allows them to pursue well-validated CNS targets that are considered "undruggable" by traditional small molecules, which have historically been the only option for crossing the blood-brain barrier.

The endgame for CZI's work is hyper-personalized, "N of one" medicine. Instead of the current empirical approach (e.g., trying different antidepressants for months), AI models will simulate an individual's unique biology to predict which specific therapy will work, eliminating guesswork and patient suffering.

A convergence of DNA sequencing, CRISPR, and AI allows scientists to move beyond just understanding biology to actively intervening. Medicine is now programming cellular behavior by rewriting DNA, representing a "step function" leap in what's achievable for treating disease at its root cause.

For intractable diseases like Parkinson's, the IGI takes an 'end-to-end' approach: building better disease models, discovering root causes, and simultaneously exploring multiple treatment modalities like direct CRISPR edits, cell therapies, and microbiome interventions. This tackles the entire problem, not just one piece.

Instead of targeting individual gene mutations in diseases like ALS, condensate science focuses on shared cellular structures where genetic risks converge. This approach creates a broader therapeutic target, potentially treating more patients with diverse genetic profiles.

Instead of focusing on symptomatic relief, Gain Therapeutics' molecule corrects a misfolded enzyme. This restores the enzyme's ability to break down toxic lipids that accumulate in nerve cells, addressing a root cause of cell damage and disease progression, rather than just managing symptoms like dopamine loss.

The next era of CNS drug development will shift from single-target therapies for late-stage disease to early intervention. This involves using biomarkers to detect disease before symptoms appear and intervening with multimodal approaches that address multiple biological pathways simultaneously, such as amyloid, tau, and metabolic deficits in Alzheimer's.

The therapeutic strategy for Friedreich's Ataxia is evolving from helping cells cope with mitochondrial stress (like the approved drug SkyClaris) to addressing the root genetic cause. The incoming pipeline is dominated by gene therapies aiming to restore the deficient frataxin gene itself, marking a fundamental shift towards a potentially curative approach.

The recent increase in neurology-focused investment and M&A isn't just a cyclical market trend. It's driven by fundamental scientific progress, including validated biological targets and improved biomarker strategies. These advances are de-risking a historically challenging field, making investors more confident in long-term commitments beyond typical market cycles.